Literature DB >> 14746806

4-1BB-ligand is regulated on human dendritic cells and induces the production of IL-12.

Diego Laderach1, Amy Wesa, Anne Galy.   

Abstract

Co-stimulation via 4-1BB and its ligand 4-1BB ligand (4-1BB-L) plays an important role in cytotoxic and pro-inflammatory immune responses. 4-1BB-L is generally described on activated antigen-presenting cells but there is limited information on its expression and function in human dendritic cells (DC). We herein compared purified CD1a+CD14- DC issued from monocytes or from hematopoietic progenitor cells (HPC). These DC expressed 4-1BB-L mRNA transcripts with highest cell surface levels on HPC-derived DC cultured with IL-1. Pro-inflammatory activation, particularly CD40 ligand+IL-1, up-regulated 4-1BB-L on DC. We confirmed reverse signaling via 4-1BB-L as immobilized 4-1BB in conjunction with CD40-L, enhanced IL-12beta mRNA and the secretion of IL-12 p70 in various APC, including monocytes. Altogether, DC may differ in T cell co-stimulation properties due to variable and regulated levels of 4-1BB-L. Data illustrate reciprocal stimulations between T cells and APC via up-regulated receptor/ligands and production of key cytokines that consolidate cellular immune responses.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14746806     DOI: 10.1016/j.cellimm.2003.11.003

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  20 in total

1.  Cross-linking of CD137 ligand modulates immune responses of thioglycollate-elicited mouse peritoneal macrophages.

Authors:  Jun-Sang Bae; Hyeong-Sup Kim; Jae Hong Park; Sang-Hyuk Park; Hyeon-Woo Lee
Journal:  Inflamm Res       Date:  2010-12-24       Impact factor: 4.575

Review 2.  Approaches to studying costimulation of human antiviral T cell responses: prospects for immunotherapeutic vaccines.

Authors:  Lena Serghides; Mariana Vidric; Tania H Watts
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

3.  CD137L-stimulated dendritic cells are more potent than conventional dendritic cells at eliciting cytotoxic T-cell responses.

Authors:  Zulkarnain Harfuddin; Shaqireen Kwajah; Adrian Chong Nyi Sim; Paul Anthony Macary; Herbert Schwarz
Journal:  Oncoimmunology       Date:  2013-11-11       Impact factor: 8.110

4.  Immunotherapy targeting 4-1BB and its ligand.

Authors:  Dass S Vinay; Byoung S Kwon
Journal:  Int J Hematol       Date:  2006-01       Impact factor: 2.490

Review 5.  Dissecting genetic control of autoimmunity in NOD congenic mice.

Authors:  William M Ridgway
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

6.  Inhibition of proliferation and induction of apoptosis in multiple myeloma cell lines by CD137 ligand signaling.

Authors:  Charles Gullo; Liang Kai Koh; Wan Lu Pang; Kian Tong Ho; Shi Hao Tan; Herbert Schwarz
Journal:  PLoS One       Date:  2010-05-26       Impact factor: 3.240

7.  4-1BB enhances proliferation of beryllium-specific T cells in the lung of subjects with chronic beryllium disease.

Authors:  Douglas G Mack; Allison K Lanham; Brent E Palmer; Lisa A Maier; Tania H Watts; Andrew P Fontenot
Journal:  J Immunol       Date:  2008-09-15       Impact factor: 5.422

8.  Analysis of CD137 and CD137L expression in human primary tumor tissues.

Authors:  Qun Wang; Pin Zhang; Qixia Zhang; Xiaoyan Wang; Jianfeng Li; Chunhong Ma; Wensheng Sun; Lining Zhang
Journal:  Croat Med J       Date:  2008-04       Impact factor: 1.351

9.  Expression of 4-1BB and 4-1BBL in thymocytes during thymus regeneration.

Authors:  Young-Mi Kim; Hye Kyung Kim; Hyo Jin Kim; Hee-Woo Lee; Seong-A Ju; Beom K Choi; Byoung S Kwon; Bong-Seon Kim; Jae-Bong Kim; Young-Tak Lim; Sik Yoon
Journal:  Exp Mol Med       Date:  2009-12-31       Impact factor: 8.718

10.  4-1BB ligand activates bystander dendritic cells to enhance immunization in trans.

Authors:  Douglas C Macdonald; Alastair Hotblack; Saniath Akbar; Gary Britton; Mary K Collins; William C Rosenberg
Journal:  J Immunol       Date:  2014-10-10       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.